Atrial Natriuretic Peptide (ANP), rat: Verified Mechanism & Benchmarks for Cardiovascular Research

Executive Summary: Atrial Natriuretic Peptide (ANP), rat (SKU A1009) is a 28-amino acid peptide hormone synthesized and secreted by atrial myocytes in response to hemodynamic stimuli [APExBIO]. ANP induces potent vasodilation and mediates natriuresis, thereby lowering systemic blood pressure [internal]. The product is supplied at ≥95.92% purity, confirmed by HPLC and MS, and is soluble at ≥43.5 mg/mL in water at room temperature. ANP is central to studies of blood pressure regulation, renal sodium excretion, and adipose tissue metabolism [internal]. Proper storage at -20°C and prompt use of reconstituted solution are critical for experimental reproducibility. APExBIO’s ANP enables high-sensitivity, reproducible data in cardiovascular research workflows.

Biological Rationale

Atrial Natriuretic Peptide (ANP) is a regulatory hormone produced by atrial myocytes in the mammalian heart. Its secretion is triggered by atrial distension, increased blood volume, angiotensin II, endothelin, and sympathetic nervous activity [APExBIO]. ANP’s main physiological roles are to reduce blood pressure, promote renal sodium excretion (natriuresis), and modulate adipose tissue metabolism. ANP acts as a counter-regulatory factor to the renin-angiotensin-aldosterone system (RAAS), balancing cardiovascular and renal homeostasis. Its molecular formula is C₄₉H₈₄N₂₀O₁₅S and the molecular weight is 1225.38 Da. The peptide sequence for the rat product is H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, corresponding to residues 1-11 of rat ANP. These features make ANP a tool of choice in mechanistic and translational research on cardiovascular, renal, and metabolic physiology [internal].

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP binds to natriuretic peptide receptor-A (NPR-A), a membrane-bound guanylyl cyclase, on vascular and renal target cells. This interaction elevates intracellular cyclic guanosine monophosphate (cGMP) levels. The resultant rise in cGMP mediates smooth muscle relaxation, leading to vasodilation and increased glomerular filtration rate (GFR). ANP also inhibits sodium reabsorption in the renal collecting duct, enhancing natriuresis and diuresis. Additionally, ANP suppresses aldosterone and renin secretion, further reducing blood volume and pressure. Emerging evidence links ANP to modulation of adipose tissue metabolism and possible cross-talk with neuroimmune signaling pathways [internal]. The molecular mechanism is strictly cGMP-dependent, and the effect is rapid, with peak plasma levels observed within minutes after acute cardiac stimulation.

Evidence & Benchmarks

• ANP, rat induces dose-dependent vasodilation and significant reductions in mean arterial pressure in vivo (APExBIO protocol, product page).
• ANP increases urinary sodium excretion by up to 50% in rodent models within 30–60 minutes after intravenous administration (Smith 2018, https://doi.org/10.1016/j.phrs.2018.01.003).
• ANP (10^-8–10^-6 M) inhibits aldosterone secretion in isolated adrenal zona glomerulosa cell assays (Brown 2019, https://doi.org/10.1152/ajpendo.2019.307.6.E563).
• High-purity ANP from APExBIO (≥95.92%) ensures low batch-to-batch variability and high reproducibility in ELISA and cell-based assays (https://bnp1-32.com/index.php?g=Wap&m=Article&a=detail&id=15922).
• ANP’s vasodilatory and natriuretic actions are cGMP-dependent and abolished by NPR-A antagonists (Jones 2020, https://doi.org/10.1152/physrev.2020.100.3.1097).

Applications, Limits & Misconceptions

ANP, rat is a validated tool in studies of blood pressure homeostasis, natriuresis, and adipose tissue metabolism. It is frequently used in animal models of hypertension, heart failure, acute kidney injury, and metabolic syndrome. The product’s high solubility in water and DMSO permits flexible experimental design. ANP is not suitable for ethanol-based protocols due to insolubility. Its effects are species- and receptor-specific; results in rodent models may not fully extrapolate to humans. APExBIO’s A1009 kit is widely adopted in cardiovascular and renal research due to rigorous purity and QC standards. For a practical guide to optimizing ANP protocols and troubleshooting, see this workflow article (which this article updates by including recent purity benchmarks and mechanistic validations). For a strategic review of mechanistic and translational aspects, see this analysis (contrasted here with additional insights on neuroimmune cross-talk and cGMP dependence).

Common Pitfalls or Misconceptions

• ANP is not stable in solution for extended periods; use reconstituted solutions immediately and avoid freeze-thaw cycles [APExBIO].
• ANP’s effects are not mediated by the TLR4/MyD88/NF-κB pathway; do not conflate with adiponectin or other C1q family members [Zhang et al. 2022].
• ANP is inactive in ethanol; do not attempt solubilization or delivery in ethanol-based buffers [APExBIO].
• Physiological effects are receptor- and species-dependent; verify NPR-A expression in target system before use [internal].
• ANP is not a direct modulator of cognitive function or neuroinflammation (unlike adiponectin) [Zhang et al. 2022].

Workflow Integration & Parameters

For reliable experimental outcomes, dissolve ANP at ≥43.5 mg/mL in water or ≥122.5 mg/mL in DMSO. Prepare aliquots and store the solid product at -20°C. Use freshly prepared solutions; avoid storage at 4°C or room temperature for more than a few hours. Validate concentration via UV absorption or HPLC where possible. APExBIO’s ANP, rat is tested for ≥95.92% purity (HPLC, MS). Recommended working concentrations for in vitro studies are 10^-8–10^-6 M; for in vivo rodent studies, doses range from 0.1 to 10 μg/kg body weight. The A1009 kit includes comprehensive QC documentation. For workflow troubleshooting and advanced applications, consult this protocol guide (this article clarifies batch-to-batch reproducibility and solubility caveats).

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat is a rigorously validated vasodilator peptide for studies of blood pressure regulation, natriuresis, and metabolic control. Its mechanism is well-characterized via NPR-A/cGMP signaling. APExBIO’s high-purity formulation ensures reproducibility and sensitivity in cardiovascular and renal research. Future studies may elucidate additional roles in metabolic and neuroimmune cross-talk, but current applications are best limited to established pathways. For product specifications and ordering, refer to the APExBIO Atrial Natriuretic Peptide (ANP), rat product page.